

Genetic Test	Institutional Price (USD\$)	CPT Codes	Z codes	Average TAT (working days)	Specimen Requirements
Rhabdoid Tumor Predisposition Syndrome Panel Testing on Tumor Block					
<p>Rhabdoid Tumor Predisposition NGS (RT-NG)</p> <p>This testing includes analysis of SMARCB1 and SMARCA4 by NGS as well as copy number analysis SMARCB1. An average coverage of >1100x will allow for the identification of mosaicism as low as 3% of the alleles.</p>	\$1,500- tumor	81405 81404	ZB68C	40*	<p>(1) Tumor block only</p> <p>(2) Blood specimen for confirmation at no additional charge if sent within a week of the tumor specimen</p>
Sanger Sequencing Based Comprehensive Testing					
NF1/SPRED1 and Other RASopathy Panel Testing					
<p>NF1 RNA-based Comprehensive Study (NF1-R)</p> <p>RNA/cDNA-based sequencing <i>and</i> copy number analysis by MLPA for the NF1 gene</p>	\$1,800	88230 (culture) 81408 81479	ZB6AF	22	<p>3-6 ml of whole blood in EDTA (purple topped) tubes</p> <p>**Sample must arrive within 60-72hours of collection**</p>
<p>NF1/SPRED1 RNA-based Comprehensive Study (NFSP-R)</p> <p>RNA/cDNA-based sequencing <i>and</i> copy number analysis by MLPA for the NF1 gene in combination with Comprehensive DNA-based sequencing and dosage (del/dup) analysis for the SPRED1 gene</p>	\$2,000	88230 (culture) 81408 81479 (x2) 81405	ZB6AJ	22	<p>3-6 ml of whole blood in EDTA (purple topped) tubes</p> <p>**Sample must arrive within 60-72hours of collection**</p>
Von Hippel Lindau Syndrome					
<p>VHL Comprehensive (VHL1)</p> <p>DNA-based sequencing <i>and</i> copy number analysis by MLPA for the VHL gene.</p>	\$650	81404 81403	ZB68F	15	<p>(1) Minimum of 5 mL whole blood in EDTA (purple topped) tubes</p> <p>(2) DNA sample (25ul volume at 3ug, O.D. value at 260:280 \geq1.8)</p>
PTEN Related Disorder Testing					
<p>PTEN Comprehensive (PTEN1)</p> <p>DNA-based testing by sequencing <i>and</i> copy number analysis by MLPA for the PTEN gene. A reduced price is charged if a pathogenic variant is found during sequencing</p>	\$1,100 \$800 (if variant identified during sequencing)	81321 81323	ZB6AH	15	<p>(1) Minimum of 5 mL whole blood in EDTA (purple topped) tubes</p> <p>(2) DNA sample (25ul volume at 3ug, O.D. value at 260:280 \geq1.8)</p>
Medium-chain Acyl-CoA Dehydrogenase deficiency (MCADD)					
<p>MCADD comprehensive analysis (DNA-based) (MCD1)</p> <p>DNA-based sanger sequencing begins with targeted testing of the c.985 A>G, p.K329E variant followed by comprehensive sequencing analysis of the ACADM gene</p>	\$250 \$550	81403 (Exon 11) 81406 (full gene)	ZB6AI	15	<p>(1) 3-6 ml whole blood in EDTA (purple topped) tubes</p> <p>(2) Oragene 575 saliva kit (provided by the MGL)</p> <p>(3) DNA sample (25ul volume at 3ug, O.D. value at 260:280 \geq1.8)</p>

Genetic Test	Institutional Price (USD\$)	CPT Codes	Z codes	Average TAT (working days)	Specimen Requirements
Fragile X syndrome					
<p>Fragile X syndrome (FRX) PCR-based analysis of the FMR1 gene If necessary for confirmatory testing, a reflex to Southern blot analysis may be performed.</p>	\$280 \$280	81243 (PCR) 81404 (Southern)	ZB6A7	15	(1) 3-6 ml whole blood in EDTA (purple topped) tubes; confirmation test specimen can be provided before or after preliminary results
Known Variant Testing					
Options Available for All Genes					
<p>Known Variant (KT2) Targeted DNA-based detection of a specific, previously known variant in any gene that is available at our lab by sequence and MLPA.</p>	\$250	81403	ZB67K	15	(1) 3-6 ml whole blood in EDTA (purple topped) tubes (2) Oragene 575 saliva kit (provided by the MGL) (3) DNA sample (25ul volume at 3ug, O.D. value at 260:280 \geq 1.8)
<p>NGS-based Known Variant (KT2-NG) Next-generation sequencing-based targeted testing with deep coverage of the alleles. This analysis provides detection of mosaicism for a known variant present at least 3-5% variant allele fraction (VAF).</p>	\$700	81479	ZB67W	30	(1) 3-6 ml whole blood in EDTA (purple topped) tubes (2) Oragene 575 saliva kit (provided by the MGL) (3) DNA sample (25ul volume at 3ug, O.D. value at 260:280 \geq 1.8) (4) Fresh, sterile semen collection using a local sperm bank/cryobank facility
<p>Prenatal Testing (PT2) Targeted detection of a specific, previously known, variant (includes maternal cell contamination (MCC) analysis)</p>	\$750	81265 (MCC) 81403	ZB67M	6**	(1) Direct CVS, (minimum 10 mg pure villi) (2) Direct amniotic fluid (min. 10 ml fluid) (3) 2 T25 flasks of cultured CVS (>70% confluent) (4) 2 T25 flasks of cultured amniocytes. (>70% confluent) (5) Maternal blood specimen for maternal cell contamination
Options Available for Select Genes					
<p>RNA-based Known Variant (RT2) RNA-based Targeted detection of a specific, previously known variant in the NF1 or NF2 gene. **Please note: it is required to contact the laboratory at 205-934-5562 or email medgenomics@uabmc.edu in advance of sending specimens for this testing option**</p>	\$500	88230 (culture) 81403	ZB68I	22	3-6 ml whole blood in EDTA (purple topped) tubes **Sample must arrive within 60-72hours of collection**

Genetic Test	Institutional Price (USD\$)	CPT Codes	Z codes	TAT (working days)	Specimen Requirements
Autosomal Recessive Polycystic Kidney Disease - PKHD1					
ARPKD Known Variant (KT2) Targeted detection of specific, previously known, PKHD1 variant(s) in family members by sequence analysis	Sequencing 1 exon: \$250	81403	ZB67K	15	(1) 3-6 ml whole blood in EDTA (purple topped) tubes (2) Oragene 575 saliva kit (provided by the MGL) (3) DNA sample (25ul volume at 3ug, O.D. value at 260:280 ≥1.8)
	Sequencing 2 exons: \$340	81403(x2)			
	MLPA: \$250	81407			
ARPKD Prenatal Targeted (PT2) Targeted detection of specific, previously known, PKHD1 variants (includes maternal cell contamination (MCC) analysis)	\$1,000	81403(x2) 81265 (MCC)	ZB67M	6	(1) Direct CVS, (minimum 10 mg pure villi) (2) Direct amniotic fluid (min. 10 ml fluid) (3) 2 T25 flasks of cultured CVS (>70% confluent) (4) 2 T25 flasks of cultured amniocytes. (>70% confluent) (5) Maternal blood specimen for maternal cell contamination
ARPKD Informativity (PKDL) Haplotype analysis by PCR of 7 markers within and flanking the PKHD1 disease interval on chromosome 6p21-cen	\$400/ individual tested	81265	ZB67G	20	Please send samples from the parents and their children for informativity results (1) 3-6 ml whole blood in EDTA (purple topped) tubes (2) Paraffin-embedded tissue blocks or whole tissue from affected individual (3) For prenatal samples, please send 2 T25 flasks of cultured CVS or 2 T25 flasks of cultured amniocytes (4) Maternal blood specimen for maternal cell contamination
ARPKD Prenatal Linkage (PKDPL) Haplotype analysis by PCR of 7 markers within and flanking the PKHD1 disease interval on chromosome 6p21-cen as a prenatal test (includes maternal cell contamination (MCC) [†] analysis)	\$500/ individual tested	81265	ZB67G	6	(1) 3-6 ml whole blood in EDTA (purple topped) tubes (2) Paraffin-embedded tissue blocks or whole tissue from affected individual (3) For prenatal samples, please send 2 T25 flasks of cultured CVS or 2 T25 flasks of cultured amniocytes (4) Maternal blood specimen for maternal cell contamination

*In the event of failure via Next Generation Sequencing (NGS), the sample will be analyzed via Sanger sequencing when possible which adds 20 working days to the average TAT.

**The TAT is not an average for prenatal analysis. The results are guaranteed within 6 working days for prenatal samples.